PQ 912, a small molecule glutaminyl cyclase (QC) inhibitor to treat both amyloidopathy and neuroinflammationĪdults with MCI or mild probable AD (Ages 50-89) Howard Feldman, University of California San Diego
Oregon trail game 5th edition tlc tips trial#
Mild to Moderate Alzheimer's Disease (Ages 50-85)Ī Seamless Phase 2A-B Randomized Double Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of PQ 912 in Patients with Early Alzheimer's DiseaseĪ Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients (PTI-125)įilamin A (FLNA), a protein critical to beta amyloid's toxicity Open-label extension of a 3-month blinded clinical trial of PTI-125 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's DiseaseĪ Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's DiseaseĪnthony Caggiano, Cognition Therapeutics IncĪdults with Mild to Moderate Alzheimer's Disease (Ages 50-85) Older adults with early AD, late mild cognitive impairment, and mild AD dementia Gamma secretase modulator (GSM)776890, an Allosteric modulator of APP processingĪ Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Alzheimer's DiseaseīMS-984923, blocks aberrant Amyloid beta activation of mGluR5ĬOG0202, A Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months Steven Lee Wagner, University Of California, San Diego Mild to moderate AD patients (Ages 50-80)Ī Single Ascending Dose / Multiple Ascending Dose Phase I study of the GSM 776890 in healthy normal subjects Susan Catalano, Cognition Therapeutics IncĬT1812, a small molecule sigma2 receptor antagonist that displaces Aβ oligomers bound to neuronal receptors at synapses Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
Non-demented adults with down syndrome (Ages 35-55)Ī Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects with Mild to Moderate Alzheimer's Disease
Rafii, University of Southern CaliforniaĪnti-Aβ immunotherapy to remove amyloid plaques Trial-Ready Cohort-Down Syndrome (TRC-DS) (TRC-DS) Clinical trials to prevent Alzheimer's Disease in Down Syndrome
0 kommentar(er)
